Navigation Links
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Date:8/5/2008

HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond

Similarly to Men and Whites

MEXICO CITY, Aug. 5 /PRNewswire-FirstCall/ -- Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the virus (reducing the amount of HIV-1) and improving the immune system (increasing CD4 cells) in women compared to men and in non-whites compared to whites, according to 48-week data presented by Abbott today at the XVII International AIDS Conference (AIDS 2008).

A retrospective sub-analysis of study M05-730 at week 48 of 96 weeks offered data on the impact of gender and race on a Kaletra-based regimen. Women and non-whites have traditionally been underrepresented in HIV studies, although these patient groups increasingly account for the vast majority of HIV infections. According to the World Health Organization, by the end of 2007, 22.5 million of the total 33.2 million people infected with HIV lived in sub-Saharan Africa. Additionally, 15.4 million of the total number of HIV-infected patients worldwide are women.

"The results showed that regardless of gender or race, Kaletra dosed once-daily or twice-daily as part of a treatment regimen achieved consistent virologic suppression in patients new to antiretroviral therapy," said Scott Brun, M.D., divisional vice president, Infectious Diseases and Immunology Development, Global Pharmaceutical Research and Development, Abbott. "Additionally, the Kaletra tablet formulation is a convenient HIV treatment option that can be taken with or without food and does not require refrigeration, which is particularly important to patients in the developing world who are disproportionately affected by HIV."

M05-730 Analysis Results

Through 48 weeks, the proportions of males and females who achieved an undetectable HIV viral load wer
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 The Pharmaceutical Care Management ... managers (PBMs), today filed a lawsuit in ... Iowa law that restricts tools ... the state,s employers and consumers.  The ... severely restricting the use of Maximum Allowable Cost (MAC) ...
(Date:9/2/2014)... Spanien und CALGARY, Alberta , September ... Vorgestellt in der "State of the Art and Featured ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, ... bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 ... gehalten hat. In seinem Vortrag mit dem Titel " ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... June 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... LLY ) today announced results from a ... BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall ... that produce insulin.) Three years of BYETTA therapy improved ...
... June 25 Novo Nordisk today presented phase 2 ... which demonstrated the potential to help achieve target glycemic control when ... at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1) ... These ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 2Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week 3
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Complications ... mastectomy and reconstruction, a new study indicates. ... mastectomy was associated with a slightly higher risk ... The study included more than 18,000 breast cancer ... a double mastectomy with breast reconstruction and were ...
(Date:9/2/2014)... who return to the emergency department within a few days ... their symptoms and have lost trust in other parts of ... study published online today in Annals of Emergency Medicine ... Perspective" ). , "When asked why they did ... their symptoms were too severe to wait until their scheduled ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Two new studies further confirm ... 6-year-olds who were breast-fed have a lower risk of ... while the other finds a similar trend when it ... benefits of breast-feeding in the immediate newborn period," said ... in New York City. She was not involved in ...
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Drinking and ... for teens, a new study suggests. Researchers analyzed ... U.S. high school seniors who said they had used ... found that drinking alcohol was associated with more unsafe ... and regret about actions while under the influence of ...
(Date:9/2/2014)... Albany, New York (PRWEB) September 02, 2014 ... lucrative business with products and services such as ... color, radio frequency-device based treatments, and breast augmentation ... market report published by U.S.-based market intelligence firm ... anti-aging treatments and products will grow to USD ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3
... ... have come together in a new format from Einstein Medical. A completely ... to create and support a rapidly evolving category: non-insurance reimbursed medicine. All ... practice, converting new patients, keeping existing patients, and better patient care. The ...
... Dr. ... announces the ten-year anniversary of his involvement with the Smiles for Life program. This annual ... to charities. , ... New York (Vocus) April 10, 2010 -- A dentist in a small community in upstate ...
... ... Dr. Jeffrey Raval has pioneered a new process to make the injections in this liquid ... that the FDA approved in 2009. , ... Denver, Colo. (PRWEB) April 10, 2010 -- As an injector trainer, one of ...
... ... ... Arizona School of Health Sciences (ATSU-ASHS) held its spring commencement ceremony for four ... earned a master of science or doctoral degree in Human Movement, Physician Assistant Studies, Audiology, ...
... guesswork, researchers say , FRIDAY, April 9 (HealthDay News) -- ... the vaccines contained both strains of influenza B instead of ... "Adding a second influenza B virus strain to the seasonal ... strain selection and help improve the vaccine,s ability to prevent ...
... , ... developer for his own use, this hand polished and sculpted mouse pad is now available ... functional addition to any desktop. , ... (PRWEB) April 9, 2010 -- Dxtra Announces the availability of the world,s only solid ...
Cached Medicine News:Health News:LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series 2Health News:LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series 3Health News:LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series 4Health News:Ballston Lake Cosmetic Dentist Excited about 10th Year Participating in Smiles for Life Program 2Health News:Ballston Lake Cosmetic Dentist Excited about 10th Year Participating in Smiles for Life Program 3Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 2Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 3Health News:ATSU –ASHS Holds Spring Commencement Ceremony 2Health News:Flu Vaccine With Both B Strains May Offer Better Protection 2
Used to introduce large devices for vascular intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Portless Sheath Introducers...
Medicine Products: